2016 Annual Meeting | Precision Neurology: Precision Directed Genetic Therapeutics

Date Tuesday 04/19/16

Time 03:30 PM - 05:30 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Peter K. Todd, MD, PhD, FAAN

Topic(s)

Learning Objectives Upon completion, participants will appreciate the different types of next gen sequencing (NGS), when to get it, and what to do with the information when they have it; understand how the functional impact of genetic mutations can be assessed; be aware of novel therapeutic approaches for people with genetically based neurological and neuro-oncological disorders; and provide patients with current information and appropriate counseling regarding next generation genetic testing.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist

Teaching Styles Didactic, Interactive, Audience Participation

Event Timeline
03:30 PM - 03:35 PM		Introduction Peter K. Todd, MD, PhD, FAAN
03:35 PM - 04:05 PM		Personalized Genomics in Neurology James R. Lupski, MD, PhD
04:05 PM - 04:25 PM		Personalized Medicine for Gliomas Eric Holland
04:25 PM - 04:45 PM		Treating a Loss-of-Function Disorder: Emerging Therapies for Friedreich Ataxia Massimo Pandolfo, MD, FAAN
04:45 PM - 05:05 PM		Targeted Treatment of Genetic Neurological Disorders with Antisense Technologies Charles A. Thornton, MD, FAAN
05:05 PM - 05:30 PM		Directed Evolution of Novel Adeno-Associated Viruses for Therapeutic Gene Delivery David Schaffer, PhD

Faculty Disclosures
James R. Lupski, MD, PhD	Dr. Lupski has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Lupski has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regeneron Genetics Center.
Eric Holland	No disclosure on file
David Schaffer, PhD	No disclosure on file
Peter K. Todd, MD, PhD, FAAN	Dr. Todd has received personal compensation in the range of $500-$4,999 for serving as a Consultant for REATA Therapeutics. Dr. Todd has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Legal services. Dr. Todd has stock in Denali Therapeutics. The institution of Dr. Todd has received research support from NIH. The institution of Dr. Todd has received research support from VA. The institution of Dr. Todd has received research support from Ann Arbor Against ALS. The institution of Dr. Todd has received research support from Packard Foudation. Dr. Todd has received intellectual property interests from a discovery or technology relating to health care. Dr. Todd has received publishing royalties from a publication relating to health care. Dr. Todd has received personal compensation in the range of $500-$4,999 for serving as a ANA Highlights module director with American Neurological Association.
Massimo Pandolfo, MD, FAAN	Dr. Pandolfo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Design Therapeutics . Dr. Pandolfo has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Pandolfo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Solid Bio. Dr. Pandolfo has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine. Dr. Pandolfo has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Design Therapeutics. Dr. Pandolfo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Larimar. Dr. Pandolfo has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology Genetics. Dr. Pandolfo has stock in Voyager Therapeutics. The institution of Dr. Pandolfo has received research support from Freidreich Ataxaia Research Alliance. Dr. Pandolfo has a non-compensated relationship as a Scientific Advisory Board with Friedreich Ataxia Research Alliance that is relevant to AAN interests or activities. Dr. Pandolfo has a non-compensated relationship as a Member-Meeting Management Committee with AAN that is relevant to AAN interests or activities.
Charles A. Thornton, MD, FAAN	Dr. Thornton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avidity. Dr. Thornton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Thornton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ionis. Dr. Thornton has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Dyne. Dr. Thornton has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pepgen. The institution of Dr. Thornton has received research support from Marigold Foundation. The institution of Dr. Thornton has received research support from NIH. The institution of Dr. Thornton has received research support from Muscular Dystrophy Association . The institution of Dr. Thornton has received research support from Dyne. The institution of Dr. Thornton has received research support from Avidity. The institution of Dr. Thornton has received research support from Ionis. Dr. Thornton has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��